MannKind
Like Dendreon, MannKind has a number of drugs in its pipeline. Unlike Dendreon, however, the company has a treatment that is much closer to market. Afrezza is a powder that is inhaled as insulin treatment for patients with diabetes.

As fellow Fool Keith Speights has pointed out, though, there are three main obstacles the company must overcome if Afrezza is to be rapidly adopted. First, the company needs more cash, but it will likely fix this through share dilution.

Second, the company will likely have to wait until the second quarter of 2013 to see if the FDA approves its new inhaler.

And finally, to have the capital it takes to manufacture and distribute Afrezza, MannKind will likely need to find a bigger company to partner with. Some Fools have already anointed Pfizer (NYSE: PFE ) as a logical partner.

News on any one of these fronts -- particularly the second and third -- would cause big moves in MannKind's stock.

http://www.fool.com/investing/general/2012/10/04/3-biotech-stocks-that-will-be-making-big-moves.aspx